Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies

Reuters2025-07-18

<a href="https://laohu8.com/S/ENSC">Ensysce Biosciences Inc.</a> Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies

Ensysce Biosciences Inc., a clinical-stage company specializing in the development of next-generation opioids, has released an investor presentation highlighting their innovative approach to analgesia. The company focuses on targeted therapy areas with blockbuster potential, utilizing transformative trypsin-controlled chemistry. Key highlights include the upcoming launch of the lead product, which has demonstrated both safety and efficacy, and a shortened development timeline through the 505(b)(2) regulatory pathway. Ensysce showcases two core technology platforms, TAAPTM for anti-abuse chemistry and MPAR® for overdose protection, to enhance drug performance. The company emphasizes its strong global patent estate and experienced management team. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2552462078?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 19:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552462078","market":"nz","top_or_hot":-1,"title":"Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a> Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a>, a clinical-stage company specializing in the development of next-generation opioids, has released an investor presentation highlighting their innovative approach to analgesia. The company focuses on targeted therapy areas with blockbuster potential, utilizing transformative trypsin-controlled chemistry. Key highlights include the upcoming launch of the lead product, which has demonstrated both safety and efficacy, and a shortened development timeline through the 505(b)(2) regulatory pathway. Ensysce showcases two core technology platforms, TAAPTM for anti-abuse chemistry and MPAR® for overdose protection, to enhance drug performance. The company emphasizes its strong global patent estate and experienced management team. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-18 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ENSC\">Ensysce Biosciences Inc.</a> Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENSCW\">Ensysce Biosciences Inc.</a>, a clinical-stage company specializing in the development of next-generation opioids, has released an investor presentation highlighting their innovative approach to analgesia. The company focuses on targeted therapy areas with blockbuster potential, utilizing transformative trypsin-controlled chemistry. Key highlights include the upcoming launch of the lead product, which has demonstrated both safety and efficacy, and a shortened development timeline through the 505(b)(2) regulatory pathway. Ensysce showcases two core technology platforms, TAAPTM for anti-abuse chemistry and MPAR® for overdose protection, to enhance drug performance. The company emphasizes its strong global patent estate and experienced management team. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250718:nNDL5Vrn40:1","article_id":"2552462078","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552462078","pubTimestamp":1752839355,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies. Ensysce Biosciences Inc., a clinical-stage company specializing in the development of next-generation opioids, has released an investor presentation highlighting their innovative approach to analgesia. The company focuses on targeted therapy areas with blockbuster potential, utilizing transformative trypsin-controlled chemistry. Key highlights include the upcoming launch of the lead product, which has demonstrated both safety and efficacy, and a shortened development timeline through the 505 regulatory pathway. Ensysce showcases two core technology platforms, TAAPTM for anti-abuse chemistry and MPAR for overdose protection, to enhance drug performance. The company emphasizes its strong global patent estate and experienced management team. You can access the full presentation through the link below.Disclaimer: This news brief was created by Publ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce Biosciences Inc.推出“下一代阿片类药物”演示文稿，通过创新的滥用保护技术针对严重疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENSC":0.9},"content_text":"Ensysce Biosciences Inc. Unveils Presentation on 'Next Generation Opioids' Targeting Severe Pain with Innovative Abuse-Protection Technologies\n    \n\nEnsysce Biosciences Inc., a clinical-stage company specializing in the development of next-generation opioids, has released an investor presentation highlighting their innovative approach to analgesia. The company focuses on targeted therapy areas with blockbuster potential, utilizing transformative trypsin-controlled chemistry. Key highlights include the upcoming launch of the lead product, which has demonstrated both safety and efficacy, and a shortened development timeline through the 505(b)(2) regulatory pathway. Ensysce showcases two core technology platforms, TAAPTM for anti-abuse chemistry and MPAR® for overdose protection, to enhance drug performance. The company emphasizes its strong global patent estate and experienced management team. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief on July 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552462078","isCrawlerRequest":true}